stockrow
Saturday 7 November 2026
Export AVTX’s income statement to Excel — free account
Avalo Therapeutics, Inc.
AVTX Healthcare Biotechnology
Avalo Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $59,000.00, down 86.6% from fiscal 2024.
- Revenue
- −70.1%
- EPS
- +56.8%
- Free cash flow
- +75.7%
Quarter to June 2026, against a year earlier
6.95
0.32
+4.83%
Follow AVTX
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
18.95 | 7.08 | 7.60 | 14.01 | |
Current Ratio |
19.31 | 7.66 | 8.14 | 14.28 | |
Net Debt/EBITDA |
12.71 | 3.93 | 4.97 | 5.84 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.55 | 0.90 | 1.04 | 0.53 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.02 | 0.11 | 0.09 | 0.08 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.46) | (0.88) | (1.06) | (1.17) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.46) | (0.88) | (1.06) | (1.17) | |
Cash per Share |
9.18 | 4.09 | 7.34 | 7.98 | |
Shareholders Equity per Share |
10.29 | 3.40 | 6.20 | 6.54 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
10.29 | 3.40 | 6.20 | 6.54 | |
Free Cash Flow |
(19.99) | (17.69) | (14.25) | (16.36) | |
Working Capital |
386.80 | 77.23 | 92.35 | 105.87 | |
Net Current Asset Value |
365.81 | 57.26 | 71.88 | 80.29 | |
| Other line items | |||||
Average Payables |
2.86 | 0.52 | 0.21 | 1.14 | |
Average Assets |
308.68 | 119.20 | 133.60 | 111.78 | |
Average Common Equity |
276.62 | 95.47 | 108.04 | 56.31 |
Columns are period end dates · fundamentals updated 26 Oct 2026